Cipla, India's third-largest drugmaker by sales, posted fourth-quarter profit above estimates on Tuesday and said it will ...

Cipla , India's No. 3 drugmaker by sales, reported a fourth-quarter profit that beat estimates on Tuesday, helped by strong ...

Cipla, India's third-biggest drugmaker by sales, reported a fourth-quarter profit that beat estimates on Tuesday, helped by ...

Cipla celebrates a significant 30% rise in net profit for Q4 FY25, with revenues growing by 9%. The company emphasizes its ...

Indian pharma giant Cipla released its Q4 FY 25 result, wherein it posted a healthy year-on-year growth of 30% in net profit ...

Profit exceeded Bloomberg estimates by 19.4 per cent, whereas the revenue fell along the expected lens growing 0.28 per cent ...

Managing Director & Global CEO Umang Vohra expressed confidence in the company's ability to expand, driven by a multi-pronged ...

Cipla Ltd reported a robust 30% YoY increase in consolidated net profit, reaching Rs 1,222 crore for Q4 FY25, driven by ...

Along with the Q4 results, Cipla announced a final dividend of Rs 13 per equity share for the financial year 2025, and a ...

Cipla beats profit estimates with strong demand for chronic condition drugs, faces supply chain issues for tumour drug.

Vohra stated that the directive appears to be primarily aimed at branded pharmaceutical products rather than generic ...

Cipla CEO says US order to lower drug prices won't impact Indian generic drugmakers. The order is likely to target branded ...